Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment

Eur J Cancer. 2018 Nov:104:243-246. doi: 10.1016/j.ejca.2018.09.014. Epub 2018 Oct 25.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Autoimmune Diseases / blood
  • Autoimmune Diseases / chemically induced*
  • Autoimmune Diseases / diagnostic imaging
  • Biomarkers
  • Diffusion Magnetic Resonance Imaging
  • Exocrine Pancreatic Insufficiency / etiology
  • Fluorine Radioisotopes
  • Fluorodeoxyglucose F18
  • Humans
  • Immunotherapy / adverse effects*
  • Lipase / blood
  • Male
  • Melanoma / drug therapy
  • Melanoma / secondary
  • Middle Aged
  • Molecular Targeted Therapy / adverse effects*
  • Neoplasm Proteins / antagonists & inhibitors*
  • Nivolumab / adverse effects*
  • Nivolumab / therapeutic use
  • Pancreatitis / blood
  • Pancreatitis / chemically induced*
  • Pancreatitis / diagnostic imaging
  • Pancreatitis / immunology
  • Positron Emission Tomography Computed Tomography
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Radiopharmaceuticals

Substances

  • Antineoplastic Agents, Immunological
  • Biomarkers
  • Fluorine Radioisotopes
  • Neoplasm Proteins
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Nivolumab
  • Lipase
  • Fluorine-18